Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 618

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Modelling of the blood–brain barrier in drug discovery and development

Cecchelli, Romeo, Berezowski, Vincent, Lundquist, Stefan, Culot, Maxime, Renftel, Mila, Dehouck, Marie-Pierre, Fenart, Laurence·2007·Nature Reviews Drug Discovery
DOI 10.1038/nrd2368
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrd2368

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 114

  1. Ballabh, P., Braun, A. & Nedergaard M. The blood–brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 16, 1–13 (2004). · DOI · Paper page
  2. Huber, J. D., Egleton R. D. & Davis, T. P. Molecular physiology and pathophysiology of tight junctions in the blood–brain barrier. Trends Neurosci. 12, 719–725 (2001). · DOI · Paper page
  3. Bradbury, M. The concept of a blood–brain barrier. (Wiley, New York, 1979).
  4. Pardridge, W. M. Peptide drug delivery to the brain. (Raven Press, New York,1991).
  5. Pardridge, W. M. et al. Comparison of in vitro and in vivo models of drug transcytosis through the blood–brain barrier. J. Pharmacol. Exp. Ther. 253, 884–891 (1990).
  6. Ghersi-Egea, J. F., Leninger-Muller, B., Suleman, G., Siest, G. & Minn, A. Localisation of drug-metabolizing enzyme activities to blood-brain interfaces and circumventricular organs. J. Neurochem. 62, 1089–1096 (1994). · DOI · Paper page
  7. El-Bacha, R. S. & Minn, A. Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain. Cell. Mol. Biol. 45, 15–23 (1999).
  8. Fenstermacher, J. D. et al. Relationship of capillary density to glucose utilization and blood flow in white and grey matter of the rat brain. Microvasc. Res. 29, 219–220 (1985).
  9. Sakurada, O. et al. Measurement of local cerebral blood flow with iodo[ 14C]antipyrine. Am. J. Physiol. 234, H59–H66 (1978). · DOI · Paper page
  10. Craigie, E. H. On the relative vascularity of various parts of the central nervous system of the albino rat. J. Comp. Neurol. 31, 429–464 (1920). · DOI
  11. Jones, E. G. On the mode of entry of blood vessels into the cerebral cortex. J. Anat. 106, 507–520 (1970).
  12. Maynard, E. A. Electron microscopy of the vascular bed of rat cerebral cortex. Am. J. Anat. 100, 409–433 (1957). · DOI · Paper page
  13. Pellerin, L. & Magistretti, P. J. Food for thought: challenging the dogmas. J. Cereb. Blood Flow Metab. 23, 1282–1286 (2003). · DOI · Paper page
  14. Newman, E. A. New roles for astrocytes: regulation of synaptic transmission. Trends Neurosci. 26, 536–542 (2003). · DOI · Paper page
  15. Edvinsson, L. & Hamel, E. Cerebral Blood Flow and Metabolism (eds Edvinsson, L. & Krause, D. N.) 43–67 (Lippincott, Williams and Wilkins, Philadelphia, 2002).
  16. Wolburg, H. et al. Modulation of tight junction structure in blood–brain barrier endothelial cells: Effects of tissue culture, second messager and cocultured astrocytes. J. Cell Sci. 107, 1347–1357 (1994). · DOI · Paper page
  17. Boado, R. J., Wang, L. & Pardridge, W. M. Enhanced expression of the blood–brain barrier GLUT1 glucose transporter gene by brain-derived factors. Brain Res. Mol. Brain Res. 22, 259–267 (1994). · DOI
  18. Raub, T. J. Signal transduction and glial cell modulation of cultured brain microvessel endothelial cell tight junctions. Am. J. Physiol. 271, C495–C503 (1996). · DOI
  19. Rist, R. J. et al. F-actin cytoskeleton and sucrose permeability of immortalised rat brain microvascular endothelial cell monolayers: Effects of cyclic AMP and astrocytic factors. Brain Res. 768, 10–18 (1997). · DOI
  20. Roux, F. et al. Regulation of γ-glutamyl transpeptidase and alkaline phosphatase activities in immortalized rat brain microvessel endothelial cell line. J. Cell Physiol. 159, 101–113 (1994). · DOI · Paper page
  21. DeBault, L. E. & Cancilla, P. A. γ-Glutamyltranspeptidase in isolated brain endothelial cells: induction by glial cells in vitro. Science 207, 653–655 (1980). · DOI · Paper page
  22. Hayashi, Y. et al. Induction of various blood–brain barrier properties in non-neuronal endothelial cells by close apposition to co-cultured astrocytes. Glia 19, 13–26 (1997). · DOI · Paper page
  23. Sobue, K. et al. Induction of blood–brain barrier properties in immortalized bovine brain endothelial cells by astrocytic factors. Neurosci. Res. 35, 155–164 (1999). · DOI · Paper page
  24. Abbott, N. J. Astrocyte-endothelial interactions and blood–brain barrier permeability. J. Anat. 200, 629–638 (2002). · DOI · Paper page
  25. Haseloff, R. F., Blasig, I. E., Bauer H. C. & Bauer, H. In search of the astrocytic factor(s) modulating blood–brain barrier functions in brain capillary endothelial cells in vitro. Cell. Mol. Neurobiol. 25, 25–39 (2005). · DOI · Paper page
  26. Pardridge, W. M., Triguero, D., Buciak, J. & Yang, J. Evaluation of cationized rat albumin as a potential blood–brain barrier drug transport vector. Exp. Neurol. 255, 893–899 (1990).
  27. Pardridge, W. M. Drug and gene targeting to the brain with molecular Trojan horses. Nature Rev. Drug Discov. 1, 131–139 (2002). · DOI · Paper page
  28. Scherrmann, J. M. Drug delivery to brain via the blood–brain barrier. Vascul Pharmacol. 38, 349–354 (2002). · DOI · Paper page
  29. Demeule, M. et al. High transcytosis of melanotransferrin (P97) across the blood–brain barrier. J. Neurochem. 83, 924–933 (2002). · DOI · Paper page
  30. Abulrob, A., Sprong, H., Van Bergen en Henegouwen, P. & Stanimirovic, D. The blood–brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J. Neurochem. 95, 1201–1214 (2005). · DOI · Paper page
  31. Benchenane, K. et al. Tissue-type plasminogen activator crosses the intact blood–brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation 111, 2241–2249 (2005). · DOI · Paper page
  32. Benchenane, K. et al. Oxygen glucose deprivation switches the transport of tPA across the blood–brain barrier from an LRP-dependent to an increased LRP-independent process. Stroke 36, 1065–1070 (2005). · DOI
  33. Lopez-Atalaya, J. P. et al. Recombinant Desmodus rotundus salivary plasminogen activator crosses the blood–brain barrier through a low-density lipoprotein receptor-related protein-dependent mechanism without exerting neurotoxic effects. Stroke 38, 1036–1043 (2007). · DOI
  34. Brillault, J., Berezowski, V., Cecchelli, R. & Dehouck, M. P. Intercommunications between brain capillary endothelial cells and glial cells increase the transcellular permeability of the blood–brain barrier during ischaemia. J. Neurochem. 83, 807–817 (2002). · DOI
  35. Hirano, A., Kawanami, T. & Llena J. F. Electron microscopy of the blood–brain barrier in disease. Microsc. Res. Tech. 27, 543–556 (1994). · DOI
  36. Joó, F. Increased production of coated vesicles in the brain capillaries during enhanced permeability of the blood–brain barrier. Br. J. Exp. Pathol. 52, 646–649 (1971).
  37. Povlishock, J. T., Becker, D. P., Sullivan, H. G. & Miller, J. D. Vascular permeability alterations to horseradish peroxidase in experimental brain injury. Brain Res. 153, 223–239 (1978). · DOI · Paper page
  38. Ford, J. M. Modulators of multidrug resistance. Preclinical studies. Hematol. Oncol. Clin. North Am. 9, 337–361 (1995). · doi:10.1016/s0889-8588(18)30098-4
  39. Schinkel, A. H. et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. Cell 77, 491–502 (1994). · DOI · Paper page
  40. Schinkel, A. H. The physiological function of drug transporting P-glycoproteins. Semin. Cancer Biol. 8, 161–170 (1997). · DOI · Paper page
  41. Schinkel, A. H. & Jonker, J. W. Mammalian drug efflux transporters of the ATP-binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 55, 3–29 (2003). · DOI · Paper page
  42. Kruh, G. D., Guo, Y., Hopper-Borge, E., Belinsky, M. G. & Chen, Z. S. ABCC10, ABCC11 and ABCC12. Pflugers Arch. 26 Jul 2006 [Epub ahead of print].
  43. Zhang, Y. Schuetz, J. D., Elmquist, W. F. & Miller, D. W. Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells. JPET 311, 449–455 (2004). · DOI · Paper page
  44. Soontornmalai, A., Vlaming, M. L. & Fritschy, J. M. Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood–brain barrier. Neurosci. 138, 159–169 (2006). · DOI
  45. Sugarawa, I., Hamada, H., Tsuruo, T. & Mori, S. Specialized localization of P-glycoprotein recognized by MRK16 monoclonal antibody in endothelial cells of the brain and the spinal cord. Jpn. J. Cancer Res. 81, 727–730 (1990). · DOI
  46. Tsuji, A. et al. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci. 51, 1427–1437 (1992). · DOI · Paper page
  47. Stewart, P. A., Beliveau, R. & Rogers, K. A. Cellular localization of P-glycoprotein in brain versus gonadal capillaries. J. Histochem. Cytochem. 44, 679–685 (1996). · doi:10.1177/44.7.8675989
  48. Beaulieu, E., Demeule, M., Ghitescu, L. & Béliveau, R. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem. J. 326, 539–544 (1997). · DOI · Paper page
  49. Scherrmann, J. M. Expression and function of multidrug resistance transporters at the blood–brain barriers. Expert Opin Drug Metab. Toxicol. 1, 233–246 (2005). · DOI
  50. Dallas, S., Miller, D. S. & Bendayan, R. Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol Rev. 58, 140–161 (2006). · DOI · Paper page
  51. Seetharaman, S., Barrand, M. A., Maskell, L. & Scheper, R. J. Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates. J. Neurochem. 70, 1151–1159 (1998). · DOI
  52. Gutmann, H., Fricker, G., Drewe, J., Toeroek, M. & Miller, D. S. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol. Pharmacol. 56, 383–389 (1999). · doi:10.1124/mol.56.2.383 · Paper page
  53. Sugiyama, Y., Kusuhara, H. & Suzuki, H. Kinetic and biochemical analysis of carrier-mediated efflux of drugs through the blood-brain and blood-cerebrospinal fluid barriers: importance in the drug delivery to the brain. J. Control Release 62, 179–186 (1999). · DOI
  54. Fenart, L. et al. Inhibition of P-glycoprotein: rapid assessment of its implication in blood–brain barrier integrity and drug transport to the brain by an in vitro model of the blood–brain barrier. Pharm. Res. 15, 993–1000 (1998). · DOI
  55. Berezowski, V., Landry, C., Dehouck, M. P., Cecchelli, R. & Fenart, L. Contribution of glial cells and pericytes to the mRNA profiles of P-glycoprotein and multidrug resistance-associated proteins in an in vitro model of the blood–brain barrier. Brain Res. 1018, 1–9 (2004). · DOI · Paper page
  56. Borst, P., Evers, R., Kool, M. & Wijnholds, J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl Cancer Inst. 92, 1295–1302 (2000). · DOI · Paper page
  57. Loscher, W. & Potschka, H. Blood–brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx. 2, 86–98 (2005). · DOI · Paper page
  58. Evers, R. et al. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J. Clin. Invest. 97, 1211–1218 (1996). · DOI · Paper page
  59. Kusuhara, H. & Sugiyama, Y. Active efflux across the blood–brain barrier:carrier family. NeuroRx. 2, 73–85 (2005). · DOI · Paper page
  60. Eisenblatter, T., Huwel, S. & Galla, H. J. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood–brain barrier. Brain Res. 971, 221–231 (2003). · DOI · Paper page
  61. Reichel, A. The role of blood–brain barrier studies in the pharmaceutical industry. Curr. Drug Metab. 7, 183–203 (2006). · DOI
  62. Joó, F. The blood–brain barrier in vitro: ten years of research on microvessels isolated from the brain. Neurochem. Int. 7, 1–25 (1985). · DOI
  63. Muruganandam, A., Herx, L. M., Monette, R., Durkin, J. P. & Stanimirovic, D. B. Development of immortalized cerebromicrovascular endothelial cell line as an in vitro model of the human blood–brain barrier. FASEB J. 11, 1187–1197 (1997). · DOI
  64. Weksler, B. B. et al. Blood–brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 19, 1872–1874 (2005). · DOI · Paper page
  65. Kannan, R., Chakrabarti, R., Tang, D., Kim, K. J. & Kaplowitz, N. GSH transport in human cerebrovascular endothelial cells and human astrocytes: Evidence for luminal localization of Na+-dependent GSH transport in HCEC. Brain Res. 852, 374–382 (2000). · DOI
  66. Demeuse, P. et al. Compartmentalized coculture of rat brain endothelial cells and astrocytes: a syngenic model to study the blood–brain barrier. J. Neurosci. Methods 121, 21–31 (2002). · DOI
  67. Perrière, N. et al. A functional in vitro model of rat blood–brain barrier for molecular analysis of efflux transporters. Brain Res. 1150, 1–13 (2007). · DOI · Paper page
  68. Coisne, C., et al. Development and characterization of a mouse syngenic in vitro blood–brain barrier model: A new tool to examine inflammatory events on cerebral endothelium. Lab Invest. 85, 735–746 (2005).
  69. Méresse, S. et al. Bovine brain endothelial cells express tight junctions and monoamine oxidase activity in long-term culture. J. Neurochem. 53, 1363–1371 (1989). · DOI · Paper page
  70. Dehouck, M. P., Méresse, S., Delorme, P., Fruchard, J. C. & Cecchelli, R. An easier, reproducible and mass production method to study the blood–brain barrier in vitro. J. Neurochem. 54, 1798–1801 (1990). One of the earliest papers describing a reproducible method for developing a BBB co-culture model with brain endothelial and glial cells that could be used in the pharmaceutical industry. Besides its use as BBB permeability and transport screen, the model has also been used in mechanistic studies in physiological and pathological conditions. · DOI · Paper page
  71. Cecchelli, R. et al. In vitro model for evaluating drug transport across the blood–brain barrier. Adv. Drug Deliv. Rev. 36, 165–178 (1999). · DOI · Paper page
  72. Rubin, L. L. et al. A cell culture model of the blood–brain barrier. J. Cell Biol. 115, 1725–1735 (1991). · DOI · Paper page
  73. O´Donnell, M. E., Martinez, A. & Sun, D. Cerebral microvascular endothelial cell NA-K-Cl co-transport: Regulation by astrocyte-conditioned medium. Am. J. Physiol. 268, C747–C754 (1995). · DOI
  74. Hurst, R. D. & Fritz, I. B Properties of an immortalised vascular endothelial/glioma cell co-culture model of the blood–brain barrier, J. Cell Physiol. 167, 81–88 (1996). · DOI · Paper page
  75. Boveri, M. et al. Induction of blood–brain barrier properties in cultured brain capillary endothelial cells: comparison between primary glial cells and C6 cell line. Glia 51, 187–198 (2005). · DOI
  76. Hoheisel, D. et al. Hydrocortisone reinforces the blood–brain barrier properties in a serum free cell culture system. Biochem. Biophys. Res. Commun. 247, 312–315 (1998). · DOI · Paper page
  77. Franke, H., Galla, H. J. & Beuckmann, C. T. An improved low-permeability in vitro-model of the blood–brain barrier: transport studies on retinoids, sucrose, haloperidol, caffeine and mannitol. Brain Res. 818, 65–71, (1999). · DOI · Paper page
  78. Zhang, Y. et al. Porcine brain microvessel endothelial cells as an in vitro model to predict in vivo blood–brain barrier permeability. Drug Metab. Dispos. 34, 1935–1943 (2006). · DOI
  79. Arthur, F. E., Shivers, R. R. & Bowman, P. D. Astrocyte-mediated induction of tight junctions in brain capillary endothelium: an efficient in vitro model. Dev. Brain Res. 36, 155–159 (1987). · DOI · Paper page
  80. Descamps, L., Coisne, C., Dehouck, B., Cecchelli, R. & Torpier, G. Protective effect of glial cells against lipopolysaccharide-mediated blood–brain barrier injury. Glia 42, 46–58 (2003). · DOI
  81. Roux, F. & Couraud, P. O. Rat brain endothelial cell lines for the study of blood–brain barrier permeability and transport functions. Cell Mol. Neurobiol. 25, 41–58 (2005). · DOI · Paper page
  82. Förster, C. et al. Occludin as direct target for glucocorticoid-induced improvement of blood–brain barrier properties in a murine in vitro system. J. Physiol. 565, 475–486 (2005). · DOI · Paper page
  83. Scism, J. L. et al. Evaluation of an in vitro coculture model for the blood–brain barrier: Comparison of human umbilical vein endothelial cells (ECV304) and rat glioma cells (C6) from two commercial sources. In Vitro Cell Dev. Biol. Anim. 35, 580–592 (1999). · doi:10.1007/s11626-999-0096-3
  84. Dejana, E. Endothelial cell–cell junctions: happy together. Nature Rev. Mol. Cell Biol. 5, 261–270, (2004). · DOI · Paper page
  85. Lundquist, S. et al. Prediction of drug transport through the blood–brain barrier in vivo: a comparison between two in vitro cell models. Pharm. Res. 19, 976–981 (2002). · DOI · Paper page
  86. Franzén, B. et al. Gene and protein expression profiling of human cerebral endothelial cells activated with tumor necrosis factor-α. Mol. Brain Res. 115, 130–146 (2003). References 90–96 demonstrate efforts in identifying genes and proteins at the brain endothelium that could be potential therapeutic targets and highlight differences between peripheral and brain endothelium. · DOI
  87. Shusta, E. V., Boado, R. J., Mathern, G. W. & Pardridge, W. M. Vascular genomics of the human brain. J. Cereb. Blood Flow Metab. 22, 245–252 (2002). · DOI
  88. Li, J. Y., Boado, R. J. & Pardridge, W. M. Rat blood–brain barrier genomics. II. J. Cereb. Blood Flow Metab. 22, 1319–1326 (2002). · DOI · Paper page
  89. Shusta, E. V., Boado, R. J. & Pardridge, W. M. Vascular proteomics and subtractive antibody expression cloning. Mol. Cell. Proteomics 1, 75–82 (2002). · DOI
  90. Shusta, E. V., Zhu, C., Boado, R. J. & Pardridge, W. M. Subtractive expression cloning reveals high expression of CD46 at the blood–brain barrier. J. Neuropathol. Exp. Neurol. 61, 597–604 (2002). · DOI
  91. Shusta, E. V., Li J. Y., Boado, R. J. & Pardridge, W. M. The Ro52/SS-A autoantigen has elevated expression at the brain microvasculature. Neuroreport 14, 1861–1865 (2003). · doi:10.1097/00001756-200310060-00021
  92. Stanness, K. A. et al. Morphological and functional characterisation of an in vitro blood–brain barrier model. Brain Res. 771, 329–342 (1997). · DOI · Paper page
  93. Cucullo, L., et al. Development of a humanized in vitro blood–brain barrier model to screen for brain penetration of antiepileptic drugs. Epilepsia 48, 505–516 (2007). · DOI · Paper page
  94. Leybaert, L. Neurobarrier coupling in the brain: a partner of neurovascular and neurometabolic coupling? J. Cereb. Blood Flow Metab. 25, 2–16 (2005). · doi:10.1038/sj.jcbfm.9600001 · Paper page
  95. Berezowski, V. et al. Transport screening of drug cocktails through an in vitro blood–brain barrier: is it a good strategy for increasing the throughput of the discovery pipeline? Pharm Res. 21, 756–760 (2004). · doi:10.1023/b:pham.0000026424.78528.11
  96. Dehouck, B. et al. A new function for the LDL receptor: transcytosis of LDL across the blood–brain barrier. J. Cell Biol. 138, 877–889 (1997). One of the first papers describing trancytosis of LDL across the BBB in vitro. · DOI · Paper page
  97. Cipolla, M. J., Crete, R., Vitullo, L. & Rix, R. D. Transcellular transport as a mechanism of blood–brain barrier disruption during stroke. Front. Biosci. 9, 777–785 (2004). · DOI
  98. Kaur, C., Sivakumar, V., Zhang, Y. & Ling, E. A. Hypoxia-induced astrocytic reaction and increased vascular permeability in the rat cerebellum. Glia 54, 826–839 (2006). · DOI · Paper page
  99. Spencer, B. J. & Verma, I. M. Targeted delivery of proteins across the blood–brain barrier. Proc. Natl Acad. Sci. USA 104, 7594–7599 (2007). · DOI · Paper page
  100. Enerson, B. E. & Drewes, L. R. The rat blood–brain barrier transcriptome. J. Cereb. Blood Flow Metab. 26, 959–973 (2006). · DOI · Paper page
  101. Fiala, M. et al. Amyloid-β induces chemokine secretion and monocyte migration across a human blood–brain barrier. Mol. Med. 4, 480–489 (1998). · DOI · Paper page
  102. Giri, R. et al. β-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am. J. Physiol. Cell Physiol. 279, C1772–C1781 (2000). · DOI · Paper page
  103. Poduslo, J. F., Curran, G. L., Wengenack, T. M., Malester, B. & Duff, K. Permeability of proteins at the blood–brain barrier in the normal adult mouse and the double transgenic mouse model of Alzheimer´s disease. Neurobiol. Dis. 8, 555–567 (2001). · DOI
  104. Iadecola, C. Atherosclerosis and neurodegeneration: unexpected conspirators in Alzheimer's dementia. Arterioscler. Thromb. Vasc. Biol. 23, 1951–1953 (2003). · DOI
  105. Iadecola, C. et al. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nature Neurosci. 2, 157–161 (1999). An interesting paper showing that vascular oxidative stress alters endothelium-dependent cerebral blood-flow responses in mice overexpressing amyloid precursor protein. · DOI · Paper page
  106. Minagar, A. & Alexander, J. S. Blood–brain barrier disruption in multiple sclerosis. Mult. Scler. 9, 540–549 (2003). · DOI · Paper page
  107. Veldhuis, W. B. et al. Interferon-β prevents cytokine-induced neutrophil infiltration and attenuates blood–brain barrier disruption. J. Cereb. Blood Flow Metab. 23, 1060–1069 (2003). · DOI
  108. Dallasta, L. M. et al. Blood–brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis. Am. J. Pathol. 155, 1915–1927 (1999). · DOI · Paper page
  109. Davies, D. C. Blood–brain barrier breakdown in septic encephalopathy and brain tumors. J. Anat. 200, 639–646 (2002). · DOI · Paper page
  110. Lo, E. H., Dalkara, T. & Moskowitz, M. A. Mechanisms, challenges and opportunities in stroke. Nature Rev. Neurosci. 4, 399–415 (2003). · DOI · Paper page
  111. Gasche, Y. et al. Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischaemia in mice: a possible role in blood–brain barrier dysfuntion. J. Cereb. Blood Flow Metab. 19, 1020–1028 (1999). · DOI · Paper page
  112. Huber, J. D. et al. Inflammatory pain alters blood–brain barrier permeability and tight junctional protein expression. Am. J. Physiol. Heart Circ. Physiol. 280, H1241–H1248 (2001). · DOI · Paper page
  113. Weidenfeller, C., Svendsen, C. N., Shusta, E. V. Differentiating embryonic neural progenitor cells induce blood–brain barrier properties. J. Neurochem. 101, 555–565 (2007). · DOI
  114. Zhang, Z. G., Zhang, L., Jiang, Q. & Chopp, M. Bone marrow-derived endothelial progenitor cells participate in cerebral neovascularization after focal cerebral ischaemia in the adult mouse. Circ. Res. 90, 284–288 (2002). · DOI · Paper page

Cited by

See all 618

Metadata

Authors
Cecchelli, R., Berezowski, V., Lundquist, S., Culot, M., Renftel, M., Dehouck, M.-P., & Fenart, L.
Venue
Nature Reviews Drug Discovery
Publisher
Springer Science and Business Media LLC
Published
2007-08
Volume
6
Issue
8
Pages
650-661
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
DOI
10.1038/nrd2368
OpenAlex
W2077216169
Cited by
618
References
9
FWCI
1.77
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Modelling of the blood–brain barrier in drug discovery and development. https://app.cochat.ai/papers/10.1038/nrd2368
The paper
Cecchelli, R., Berezowski, V., Lundquist, S., Culot, M., Renftel, M., Dehouck, M.-P., & Fenart, L. (2007). Modelling of the blood–brain barrier in drug discovery and development. Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd2368

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.